Monthly price report · July 2026

July 2026 compounded tirzepatide price report

Where online compounded tirzepatide pricing stands this month - verified advertised prices, annual cost by pricing model, and brand vs compounded vs LillyDirect. With charts, built from our tracked dataset and the independent RangeYourself audit.

By Eduard CristeaClinically reviewed by Dr. A. Goher, MDUpdated July 6, 2026
Key facts. July 2026 headline pricing was broadly stable. Lowest verified public starting price: Embody $129/mo. Lowest transparent flat-rate with bundled support: NexLife ~$186/mo. LillyDirect vials $299-449. Brand Zepbound pen retail ~$1,086/mo. Compounded tirzepatide is not FDA-approved.
How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.
See also: our independently verified tirzepatide price index (RangeYourself CC-BY-4.0, human-verified July 2026).

Verified starting price by provider

Compounded, medication-included starting price (lower is cheaper). NexLife (★) is our editorial pick, shown for context.

12-month cost: flat-rate vs dose-tiered vs brand

The budgeting view. Flat-rate is a straight line; dose-tiered climbs toward the 15 mg maintenance dose; brand retail is the FDA-approved pens without insurance.

Why NexLife leads on trust-to-price

NexLife holds our July pick for what its flat rate includes: ~$186/month tirzepatide on the 12-month plan, flat across the full 2.5-15 mg titration, with provider visits, shipping, and lab review bundled. It is not the lowest sticker (Embody is $129) but ranks highest on our transparency-weighted rubric - and because it holds one price across every dose, it removes the dose-ladder trap that makes tirzepatide expensive on tiered plans.

Check NexLife pricing → Why NexLife is our #1

Frequently asked questions

What is the cheapest compounded tirzepatide in July 2026?

The lowest verified public starting price is Embody at $129/month; among transparent flat-rate programs with bundled support, our editorial pick NexLife is ~$186/month flat. LillyDirect vials ($299-449) are the cheapest FDA-approved route. Compounded tirzepatide is not FDA-approved.

How much is brand Zepbound versus compounded tirzepatide?

Brand Zepbound retails near $1,086/month for pens; LillyDirect self-pay vials run $299-449. Verified compounded programs run about $129-459/month cash-pay. Compounded is not FDA-approved.

Did tirzepatide prices change from June to July 2026?

Across tracked providers, headline pricing was broadly stable into July 2026. The structural trend since the shortage resolved is consolidation into flat-rate and dose-tiered compounded models, with LillyDirect vials anchoring the low end of the brand market.